Genomic Health Announces Study Confirming Prognostic Value Of Oncotype DX(R) Recurren
 

Genomic Health, Inc. (Nasdaq: GHDX) announced results of a multi-center Japanese study demonstrating that the Oncotype DX breast cancer assay had significant prognostic value in Japanese women with estrogen receptor-positive early-stage breast cancer. Oncotype DX identified a large portion of patients in Japan who had estrogen receptor-positive early-stage breast cancer as having a low likelihood of distant recurrence.

More...